EASY BIO, Inc.: debt-to-equity, ROE and more
KOSDAQ, Legal name EASY BIO, Inc.
Latest figures are the FY2025 consolidated summary statements.
Latest fiscal year ratios (computed here)
- Debt/equity
- 188.4%
- Equity ratio
- 34.7%
- ROE
- 25.8%
- Op. margin
- 9.4%
- Rev. growth
- 24.1%
- Interest coverage
- n/a
Condition flags
- Operating profit for 5 straight years.
- Total equity is above paid-in capital. Not capital-impaired.
Interest coverage and dividends (OpenDART)
Interest expense and dividends come from DART's OpenDART annual-report filings, not the FSC summary statements used above. The source differs from the other tables on this page.
Interest coverage = operating profit ÷ interest expenseNo interest expense value yet for this company. Most companies fold interest expense into a single finance-costs line on their income statement, so it cannot be pulled out separately. Interest coverage is not computed here.
Dividends, last 3 fiscal years
| Fiscal year | Cash dividend per share | Payout ratio |
|---|---|---|
| 2025 | ₩250 | 29.8% |
| 2024 | ₩200 | 33.8% |
| 2023 | ₩100 | 22.0% |
Cash dividends for 3 straight years (only the 3 years OpenDART returns).
Source values from the OpenDART (금융감독원 전자공시) annual report. Report fiscal year 2025.
Ratios by year (computed here)
Debt-to-equity = total liabilities ÷ total equity × 100Equity ratio = total equity ÷ total assets × 100ROE = net income ÷ year-end total equity × 100Operating margin = operating profit ÷ revenue × 100Revenue growth = (this year − last year) ÷ last year × 100
Computed from the source figures above with these formulas. Where the source's own debt-to-equity differs from ours, both are shown for that year.
| Fiscal year | Debt/equity | Equity ratio | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| FY2021 consolidated | 159.2% | 38.6% | 23.9% | 13.0% | n/a |
| FY2022 consolidated | 198.8% | 33.5% | 17.7% | 10.4% | 20.2% |
| FY2023 consolidated | 160.0% | 38.5% | 24.3% | 12.5% | 6.3% |
| FY2024 consolidated | 305.4% | 24.7% | 22.4% | 8.4% | 132.4% |
| FY2025 consolidated | 188.4% | 34.7% | 25.8% | 9.4% | 24.1% |
Source figures (FSC summary statements)
Amounts are the source values, shortened. A cell reported as zero may be blank in the source, so it is not used in any ratio.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | ₩129.5B | ₩155.6B | ₩165.4B | ₩384.3B | ₩476.9B |
| Operating profit | ₩16.8B | ₩16.2B | ₩20.6B | ₩32.4B | ₩45.0B |
| Pre-tax income | ₩14.1B | ₩12.0B | ₩20.1B | ₩26.4B | ₩38.7B |
| Net income | ₩10.8B | ₩9.3B | ₩16.1B | ₩19.9B | ₩29.3B |
| Total assets | ₩117.7B | ₩157.8B | ₩172.0B | ₩360.0B | ₩327.5B |
| Total liabilities | ₩72.3B | ₩105.0B | ₩105.9B | ₩271.2B | ₩213.9B |
| Total equity | ₩45.4B | ₩52.8B | ₩66.2B | ₩88.8B | ₩113.6B |
| Paid-in capital | ₩3.4B | ₩3.4B | ₩3.4B | ₩3.4B | ₩3.4B |
| Debt/equity (source value) | 159.2% | 198.8% | 160.0% | 305.4% | 188.4% |
Company outline (FSC)
- Market
- KOSDAQ
- Fiscal year end
- Dec
- Founded
- 2020-05-01
- Listed
- 20/06/05
- Employees
- 143
- Auditor
- 이촌회계법인
- Audit opinion
- 적정의견
- Corporate reg. no.
- 1101117474424
- Outline updated
- 2026-09-24
Check the original filings
Read the annual report and audit report before you decide anything. The link opens a DART search for this company's name.
Search DART for 이지바이오Computed from the Financial Services Commission's company outline and summary statements (data.go.kr). Data as of 2026-09-24.